We are relentless in our pursuit of a world without bleeds. Beyond delivering new medicines, we are dedicated in our efforts to encourage early diagnosis and propel patients towards optimal personalized care, and help them remain on the right therapy with the goal of achieving the best possible long-term outcomes.
We are investigating important scientific platforms, such as antibody therapy, so that we are best positioned to discover innovative therapies tomorrow—while ensuring patients are cared for with use of our broad portfolio today.
We’re committed to caring for patients with bleeding disorders including:
Hemophilia is an inherited bleeding disorder that mostly affects males. People with hemophilia lack or have low levels of certain proteins called clotting factors, so their blood doesn’t clot properly. Over 400,000 people worldwide are living with hemophilia. More precisely, in Belgium, there are about 1015 patients affected with Hemophilia type A and about 243 patients affected with Hemophilia type B.
https://www.ahvh.be/informations/statistiques/46-combien-de-patients-hemophiles-en-belgique.html Accessed January 24, 2022.